In this interview with Plastic Surgery Practice , Joely Kaufman, MD, a board-certified dermatologist, fellow of the American Academy of Dermatology, and director of Skin Associates of South Florida in Coral Gables, discusses findings from the study, Survey of Facial Aesthetic Concerns and Treatment Trends Following GLP-1 Agonist-Associated Weight Loss , presented at the 2025 American Society for Dermatologic Surgery Annual Meeting, and shares how plastic surgeons and other aesthetic providers are adapting their treatment algorithms to address the unique facial changes associated with GLP-1related weight loss
Experts say the results point to the notion that the drug should continue to be used as directed, with close consultation from medical professionals.
The age-related decline in GHK-Cu, rather than the onset of new disease processes, is thought to be the underlying cause of neurodegeneration
GLP-1 medicationsincluding GLP-1 agonists like semaglutide and dual agonists like tirzepatidework by targeting incretin pathways to reduce hunger, slow digestion, and improve blood sugar regulation
Systemic wound healing or regenerative protocols may use higher doses under physician supervision
